A Comprehensive Systematic Review of Association of SGLT2 Inhibitors to Renal Protection in Patients with Diabetic Kidney Disease
Keywords:
SGLT2 inhibitors, diabetic kidney disease, renal protection, albuminuria, chronic kidney disease, empagliflozin, canagliflozin, dapagliflozin, systematic reviewAbstract
Introduction: Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease worldwide despite optimal renin-angiotensin-aldosterone system blockade. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential renoprotective agents, yet the totality of evidence across diverse study designs, populations, and renal outcomes requires comprehensive synthesis. This systematic review aims to evaluate the association between SGLT2 inhibitors and renal protection in patients with DKD, synthesizing evidence from randomized controlled trials, observational studies, and meta-analyses.
Methods: A comprehensive systematic review was conducted following PRISMA guidelines. We screened studies based on predefined criteria including adult patients (≥18 years) with DKD, SGLT2 inhibitor intervention, renal outcomes reported (eGFR decline, albuminuria reduction, progression to ESRD), study designs including RCTs and observational studies, follow-up ≥12 weeks, and exclusion of case reports/series. Data extraction encompassed study characteristics, SGLT2 inhibitor details, population demographics, renal outcomes, effect sizes, mechanisms, and adverse effects. Methodological quality was assessed using Cochrane risk of bias tools and Newcastle-Ottawa Scale.
Results: From the evidence base comprising over 90,000 participants across landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) and numerous meta-analyses, SGLT2 inhibitors consistently demonstrated significant renal protection. Pooled analyses showed 30-40% risk reduction in composite renal outcomes (HR 0.61-0.71, 95% CI), 25-35% reduction in albuminuria progression, and 30% slower eGFR decline. Benefits were consistent across subgroups including baseline eGFR <30 mL/min/1.73m², elderly patients, and varying albuminuria levels. Hemodynamic mechanisms (reduced intraglomerular pressure via tubuloglomerular feedback) and metabolic effects (glycemic control, weight reduction) contributed independently of HbA1c changes. Safety analysis revealed initial eGFR dip (typically <5 mL/min/1.73m², reversible) without increased acute kidney injury risk; genital infections were increased but rarely severe.
Discussion: This comprehensive synthesis confirms SGLT2 inhibitors as foundational therapy for renal protection in DKD, with benefits extending across CKD stages 2-4 and independent of diabetes duration or glycemic control. The consistency between RCT efficacy and real-world effectiveness supports broad implementation. Mechanisms involve hemodynamic normalization, anti-inflammatory effects, and improved mitochondrial function.
Conclusion: SGLT2 inhibitors provide robust, multi-mechanistic renal protection in DKD with favorable safety profiles. We recommend their early initiation in DKD patients regardless of glycemic control, with monitoring for reversible eGFR decline and volume status. Future research should address optimal combination strategies with newer agents and long-term outcomes beyond five years.
References
A. B. A. Andrade. “SGLT-2 Inhibitors and Nephroprotection: A Systematic Review and Meta-Analysis,” 2020.
A. Forbes, R. Suckling, W. Hinton, M. Feher, D. Banerjee, N. Cole, S. de Lusignan, and P. Swift. “Sodium‐glucose Cotransporter‐2 Inhibitors and Kidney Outcomes in Real‐world Type 2 Diabetes Populations: A Systematic Review and Meta‐analysis of Observational Studies.” Diabetes, Obesity and Metabolism, 2023.
A. Korbut, and V. Klimontov. “Empagliflozin: A New Strategy for Nephroprotection in Diabetes,” 2017.
A. Liu, Serena Low, E. Yeoh, Eng Kuang Lim, C. Renaud, S. Teoh, Grace Feng Ling Tan, et al. “A Real-World Study on SGLT2 Inhibitors and Diabetic Kidney Disease Progression.” Clinical Kidney Journal, 2022.
A. Mahendra, Nur Samsu, Atma Gunawan, and Achmad Rifai. “#2934 SGLT-2 INHIBITORS DELAY KIDNEY FAILURE PROGRESSION AND REDUCE NEED OF DIALYSIS IN CHRONIC KIDNEY DISEASE PATIENTS: A META-ANALYSIS.” Nephrology, Dialysis and Transplantation, 2023.
A. Mima. “Renal Protection by Sodium-Glucose Cotransporter 2 Inhibitors and Its Underlying Mechanisms in Diabetic Kidney Disease.” Journal of Diabetes and Its Complications, 2018.
A. Piperidou, C. Loutradis, and P. Sarafidis. “SGLT-2 Inhibitors and Nephroprotection: Current Evidence and Future Perspectives.” Journal of Human Hypertension, 2020.
A. Piperidou, P. Sarafidis, A. Boutou, C. Thomopoulos, C. Loutradis, M. Alexandrou, A. Tsapas, and A. Karagiannis. “The Effect of SGLT-2 Inhibitors on Albuminuria and Proteinuria in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of Hypertension, 2019.
A. Romano. “Update on the Impact of Sodium-Glucose Cotransporter Inhibitors in Diabetic Kidney Disease Progression,” 2020.
A. Roy, A. Maiti, A. Sinha, Arjun Baidya, A. Basu, Dasarathi Sarkar, D. Sanyal, et al. “Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement.” Diabetes Therapy, 2020.
A. Scheen. “Efficacy and Safety Profile of SGLT2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease.” Expert Opinion on Drug Safety, 2020.
———. “Sodium–Glucose Cotransporter Type 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.” Nature Reviews Endocrinology, 2020.
———. “The Current Role of SGLT2 Inhibitors in Type 2 Diabetes and Beyond: A Narrative Review.” Expert Review of Endocrinology & Metabolism, 2023.
A. Scheen, and P. Delanaye. “[SGLT2 Inhibitors: Focus on Kidneys and Nephroprotection].” Revue Medicale Suisse, 2021.
A. Tansawet, Panu Looareesuwan, H. Teza, S. Boongird, Gareth J. Mckay, J. Attia, O. Pattanaprateep, and A. Thakkinstian. “Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Chronic Kidney Disease Progression: A Multi-State Survival Model.” Diabetology & Metabolic Syndrome, 2024.
Agus Layanto, Lely Kusumaningrum, Cynthia Arsita, and Fenny Halim. “Integrating Sglt-2 Inhibitors into the Clinical Management of Type 2 Diabetes Mellitus and Chronic Kidney Disease: Current Evidence and Future Outlook.” Asian Journal of Medicine and Health, 2024.
Alexander Turchin, Lucia C. Petito, Emma Hegermiller, Ryan M. Carnahan, Andrea R. Devries, Satyender Goel, M. CECILIA LANSANG, et al. “415-P: Proteinuria and Progression of Kidney Disease in Patients with T2D Treated with SGLT2i and GLP-1RA—A Target Trial Emulation.” Diabetes, 2025.
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, and Natnicha Poonchuay. “Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors Versus DPP-4 Inhibitors: A Real-World Observational Study.” Advances in Pharmacological and Pharmaceutical Sciences, 2023.
Arnaud D. Kaze, M. Zhuo, Seoyoung C. Kim, Elisabetta Patorno, and Julie M. Paik. “Association of SGLT2 Inhibitors with Cardiovascular, Kidney, and Safety Outcomes Among Patients with Diabetic Kidney Disease: A Meta-Analysis.” Cardiovascular Diabetology, 2022.
Atit Dharia, Abid Khan, V. Sridhar, and D. Cherney. “SGLT2 Inhibitors: The Sweet Success for Kidneys.” Annual Review of Medicine, 2023.
Ayesha Saleem, Shahroz M. Khan, Imdad Ullah, Syed S. Nasim, Sajedur Rahman, and Arslan Tayyab. “Investigating the Role of Sodium-Glucose Cotransporter-2 Inhibitors in Slowing Down the Diabetic Kidney Disease Progression: A Meta-Analysis of Randomized Control Trials.” Journal of Advances in Medicine and Medical Research, 2024.
B. Fernandez-Fernandez, P. Sarafidis, M. Kanbay, J. Navarro-González, M. Soler, J. Górriz, and A. Ortiz. “SGLT2 Inhibitors for Non-Diabetic Kidney Disease: Drugs to Treat CKD That Also Improve Glycaemia.” Clinical Kidney Journal, 2020.
B. Fernandez-Fernandez, P. Sarafidis, M. Soler, and A. Ortíz. “EMPA-KIDNEY: Expanding the Range of Kidney Protection by SGLT2 Inhibitors.” Clinical Kidney Journal, 2023.
B. Neuen, M. Jardine, and V. Perkovic. “Sodium-Glucose Cotransporter 2 Inhibition: Which Patient with Chronic Kidney Disease Should Be Treated in the Future?” Nephrology, Dialysis and Transplantation, 2020.
B. Neuen, T. Young, H. Heerspink, B. Neal, V. Perkovic, L. Billot, K. Mahaffey, et al. “SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.” The Lancet Diabetes and Endocrinology, 2019.
B. Pasternak, V. Wintzell, M. Melbye, B. Eliasson, A. Svensson, S. Franzén, S. Gudbjörnsdottir, et al. “Use of Sodium-Glucose Co-Transporter 2 Inhibitors and Risk of Serious Renal Events: Scandinavian Cohort Study.” British Medical Journal, 2020.
B. Spiazzi, G. Piccoli, L. F. Wayerbacher, J. O. P. Lubianca, Bruno G Scalco, Mariana H Scheffler, Bruna L Fraga, Verônica Colpani, and F. Gerchman. “SGLT2 Inhibitors and Kidney Outcomes Across the Spectrum of Kidney Disease: A Systematic Review and Meta-Analysis.” American Society of Nephrology. Clinical Journal, 2024.
Buchun Jiang, Zhiwen Cheng, Dongjie Wang, Fei Liu, Jingjing Wang, Haidong Fu, and Jianhua Mao. “Unveiling the Podocyte-Protective Effect of Sodium-Glucose Cotransporter-2 Inhibitors.” Kidney Research and Clinical Practice, 2024.
C. Baigent, J. Emberson, R. Haynes, W. Herrington, P. Judge, M. Landray, Kaitlin J. Mayne, et al. “Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials.” The Lancet, 2022.
C. Bailey, C. Day, and S. Bellary. “Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.” Current Diabetes Reports, 2022.
C. Deerochanawong. “Use of SGLT-2 Inhibitors in Patients with T2DM and Kidney Disease: An Asian Perspective and Expert Recommendations,” 2019.
C. Garofalo, S. Borrelli, M. Liberti, M. Andreucci, G. Conte, R. Minutolo, M. Provenzano, and L. De Nicola. “SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.” Medicina, 2019.
C. Jung. “New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors.” Endocrinology and Metabolism, 2021.
C. Khoo, C. Deerochanawong, Chan Siew Pheng, B. Matawaran, W. Sheu, J. Chan, A. Mithal, et al. “Use of Sodium‐glucose Co‐transporter‐2 Inhibitors in Asian Patients with Type 2 Diabetes and Kidney Disease: An Asian Perspective and Expert Recommendations.” Diabetes, Obesity and Metabolism, 2020.
C. Mende. “Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.” Advances in Therapy, 2021.
C. Wanner. “EMPA-REG OUTCOME: The Nephrologist's Point of View.” American Journal of Medicine, 2017.
Carlos Ignacio Reyes-Farias, Marcelo Reátegui-Díaz, Franco Romaní-Romaní, and Larry Prokop. “The Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease with or Without Type 2 Diabetes Mellitus on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis.” PLoS ONE, 2023.
Catarina Almeida, Leonor Silva, T. Costa, D. Lopes, V. Faria, E. Suarez, R. Veríssimo, R. Caçola, P. Gil, and L. G. M. Andrade. “MO647RENOPROTECTIVE EFFECT OF SGLT2 INHIBITORS AFTER FIVE YEARS OF TREATMENT: AN OBSERVATIONAL STUDY,” 2021.
Chalmoukou Konstantina, Polyzos Dimitris, Manta Eleni, Tatakis Fotis, Konstantinidis Dimitris, Thomopoulos Costas, and Tsioufis Costas. “Renal Outcomes Associated with Glucose-Lowering Agents: Systematic Review and Meta-Analysis of Randomized Outcome Trials.” European Journal of Internal Medicine, 2021.
Chao Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Z. Nie, Yu Zhao, and Beiyan Bao. “Effect of SGLT2 Inhibitor on Renal Function in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” International Urology and Nephrology, 2019.
Charlotte C. van Ruiten, Anne C. Hesp, and D. V. van Raalte. “Sodium Glucose Cotransporter-2 Inhibitors Protect the Cardiorenal Axis: Update on Recent Mechanistic Insights Related to Kidney Physiology.” European Journal of Internal Medicine, 2022.
Chen Wang, Yue Zhou, Zi‐Li Kong, Xiang Wang, W. Lv, Zhuang Geng, and Yangang Wang. “The Renoprotective Effects of Sodium‐glucose Cotransporter 2 Inhibitors Versus Placebo in Patients with Type 2 Diabetes with or Without Prevalent Kidney Disease: A Systematic Review and Meta‐analysis.” Diabetes, Obesity and Metabolism, 2019.
Chen, and Zhao. “Effect of SGLT 2 Inhibitor on Renal Function in Patients with Type 2 Diabetes Mellitus : A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” 2019.
Chu-Hsuan Shiau, Li-Yun Tsau, Chih-Chin Kao, Yu-Ching Peng, Chyi-Huey Bai, Jeng-Cheng Wu, and Wenjuan Hou. “Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.” International Urology and Nephrology, 2023.
Claire C J Dekkers, and R. Gansevoort. “Sodium-Glucose Cotransporter 2 Inhibitors: Extending the Indication to Non-Diabetic Kidney Disease?” Nephrology, Dialysis and Transplantation, 2020.
D. Cherney, A. Odutayo, R. Aronson, J. Ezekowitz, and J. Parker. “Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.” Journal of the American College of Cardiology, 2019.
D. Giugliano, L. De Nicola, M. Maiorino, G. Bellastella, and K. Esposito. “Type 2 Diabetes and the Kidney: Insights from Cardiovascular Outcome Trials.” Diabetes, Obesity and Metabolism, 2019.
D. Giugliano, M. Longo, L. Scappaticcio, G. Bellastella, M. Maiorino, and K. Esposito. “SGLT-2 Inhibitors and Cardiorenal Outcomes in Patients with or Without Type 2 Diabetes: A Meta-Analysis of 11 CVOTs.” Cardiovascular Diabetology, 2021.
D. Giugliano, M. Longo, P. Caruso, M. Maiorino, G. Bellastella, and K. Esposito. “Sodium‐glucose Co‐transporter‐2 Inhibitors for the Prevention of Cardiorenal Outcomes in Type 2 Diabetes: An Updated Meta‐analysis.” Diabetes, Obesity and Metabolism, 2021.
D. McGuire, W. Shih, F. Cosentino, B. Charbonnel, D. Cherney, S. Dagogo-Jack, R. Pratley, et al. “Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes.” JAMA Cardiology, 2020.
D. V. O'Hara, D. V. O'Hara, B. Neuen, B. Neuen, M. Jardine, and M. Jardine. “Kidney and Cardiovascular Protection with SGLT2 Inhibitors: Lessons from Cardiovascular Outcome Trials and CREDENCE.” JN. Journal of Nephrology (Milano. 1992), 2020.
Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, T. Yokota, K. Sango, and K. Utsunomiya. “SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.” International Journal of Molecular Sciences, 2017.
Davide Margonato, G. Galati, S. Mazzetti, R. Cannistraci, G. Perseghin, A. Margonato, and A. Mortara. “Renal Protection: A Leading Mechanism for Cardiovascular Benefit in Patients Treated with SGLT2 Inhibitors.” Heart Failure Reviews, 2020.
Debdipta Bose, Miteshkumar Maurya, and M. Konwar. “Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Outcomes in Patients of Diabetes Mellitus: A Meta-Analysis of Landmark Renal and Cardiovascular Outcome Trials.” Indian Journal of Pharmacology, 2023.
Dorsa Jahangiri, Udit Narayan Padhi, H. Verma, B. Lakkakula, R. Valizadeh, and Hamid Nasri. “Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i); as a Preventive Factor of Kidney Failure in Patients with Type 2 Diabetes; a Meta-Analysis of Randomized Controlled Trials.” Journal of Renal Injury Prevention, 2021.
E. Brown, J. Wilding, U. Alam, T. Barber, J. Karalliedde, and D. Cuthbertson. “The Expanding Role of SGLT2 Inhibitors Beyond Glucose-Lowering to Cardiorenal Protection.” Annals Medicus, 2020.
E. Elenjickal, C. Travlos, Judy M Luu, Serge Lemay, Rita S. Suri, and Thomas A. Mavrakanas. “Efficacy and Safety of SGLT-2 Inhibitors in Patients With and Without Advanced CKD: A Systematic Review and Meta-Analysis.” American Society of Nephrology. Clinical Journal, 2025.
E. Nelaj, Irida Kecaj, Julinda Feracaku, Kei Xhixhabesi, and M. Tase. “Benefits of SGLT2 Inhibitors on Renal and Cardiovascular Protection, in Diabetic Patients.” South Eastern European Journal of Public Health, 2024.
Emre Leventoğlu, and S. Bakkaloğlu. “SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?” Klinische Pädiatrie, 2024.
F. Giorgino, J. Vora, P. Fenici, and A. Solini. “Renoprotection with SGLT2 Inhibitors in Type 2 Diabetes over a Spectrum of Cardiovascular and Renal Risk.” Cardiovascular Diabetology, 2020.
F. Lin, Chi‐Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang, and H. Ou. “Renoprotective Effect of SGLT-2 Inhibitors Among Type 2 Diabetes Patients with Different Baseline Kidney Function: A Multi-Center Study.” Cardiovascular Diabetology, 2021.
G. Chan, J. Ng, K. Chow, and C. Szeto. “SGLT2 Inhibitors Reduce Adverse Kidney and Cardiovascular Events in Patients with Advanced Diabetic Kidney Disease: A Population-Based Propensity Score-Matched Cohort Study.” Diabetes Research and Clinical Practice, 2022.
G. Park, Byung-Don Choi, Soyoung Kang, Bomin Kim, and M. Chang. “Sodium–Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting.” Journal of Clinical Medicine, 2022.
G. Schernthaner, P. Groop, P. Kalra, C. Ronco, and M. Taal. “Sodium‐glucose Linked Transporter‐2 Inhibitor Renal Outcome Modification in Type 2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk.” Diabetes, Obesity and Metabolism, 2020.
Gian Paolo Fadini, Enrico Longato, M. Morieri, Enzo Bonora, Agostino Consoli, B. Fattor, M. Rigato, et al. “Comparative Renal Outcomes of Matched Cohorts of Patients with Type 2 Diabetes Receiving SGLT2 Inhibitors or GLP-1 Receptor Agonists Under Routine Care.” Diabetologia, 2024.
H. Cao, Tao Liu, Li Wang, and Q. Ji. “393-P: SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-Analysis.” Diabetes, 2022.
———. “Comparative Efficacy of Novel Antidiabetic Drugs on Cardiovascular and Renal Outcomes in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta‐analysis.” Diabetes, Obesity and Metabolism, 2022.
H. Heerspink, A. Karasik, M. Thuresson, Cheli Melzer-Cohen, G. Chodick, K. Khunti, John P H Wilding, et al. “Kidney Outcomes Associated with Use of SGLT2 Inhibitors in Real-World Clinical Practice (CVD-REAL 3): A Multinational Observational Cohort Study.” The Lancet Diabetes and Endocrinology, 2020.
H. Heerspink, M. Kosiborod, S. Inzucchi, and D. Cherney. “Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors.” Kidney International, 2018.
H. Nagasu, Y. Yano, Hiroshi Kanegae, Hiddo J. L. Heerspink, M. Nangaku, Y. Hirakawa, Y. Sugawara, et al. “Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-World Clinical Practice: The Japan Chronic Kidney Disease Database.” Diabetes Care, 2021.
H. Takashima, Yoshinori Yoshida, Chinami Nagura, T. Furukawa, Ritsukou Tei, T. Maruyama, Noriaki Maruyama, and M. Abe. “Renoprotective Effects of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Type 2 Diabetes Patients with Chronic Kidney Disease: A Randomized Open-Label Prospective Trial.” Diabetes & Vascular Disease Research, 2018.
Haiyan Cao, Youxia Liu, Zhixia Tian, Yuhang Lian, J. Jia, Ming Liu, and Dong Li. “Sodium-Glucose Cotransporter 2 Inhibitors Benefit to Kidney and Cardiovascular Outcomes for Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease 3b-4: A Systematic Review And Meta-Analysis of Randomized Clinical Trials.” Diabetes Research and Clinical Practice, 2021.
Hema Boddula, R. Shivani, Nayak S P Srinivas, Jitendra Vaghasia, G. S. Chakraborthy, Snigdha Das Mandal, and Prajwal Ghatol. “The Effectiveness of SGLT2 Inhibitors in CKD Patients.” Journal of Drug Delivery and Therapeutics, 2023.
Honghong Zou, Baoqin Zhou, and Gaosi Xu. “SGLT2 Inhibitors: A Novel Choice for the Combination Therapy in Diabetic Kidney Disease.” Cardiovascular Diabetology, 2017.
Hongru Yan, Yi Wen, and Bicheng Liu. “Renoprotective Mechanisms of SGLT2 Inhibitor in Diabetic Kidney Disease.” Diabetic Nephropathy, 2021.
Husam M. Salah, S. Al’Aref, M. Khan, Malek Al‐Hawwas, S. Vallurupalli, J. Mehta, J. Mounsey, et al. “Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Kidney Outcomes-Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.” American Heart Journal, 2020.
Hyeong-Kyu Park, Sang-Joon Park, Soon-Hyo Kwon, Dong-Won Byun, and K. Suh. “COMPARISON OF RENAL PROTECTIVE EFFECTS BETWEEN SGLT2 INHIBITORS AND DPP4 INHIBITORS IN TYPE 2 DIABETES IN REAL-WORLD CLINICAL PRACTICE.” Journal of the ASEAN Federation of Endocrine Societies, 2023.
I. Idris. “Empagliflozin Reduced Progression of Kidney Disease and Cardiovascular Death in Patients with or Without Diabetes Who Are at High Risk of Disease Progression.” Diabetes, Obesity and Metabolism Now, 2023.
Issa Kawalit, A. Al-Omari, Zeina H Kalaji, Asad Al-Tirawi, M. Eltwal, and Abbas El-Khatib. “Renal Outcomes with Sodium-Glucose Cotransporters 2 Inhibitors in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease Stages 3b-4.” Medical Research Archives, 2024.
J. C. De La Flor, Daniel Villa, Leónidas Cruzado, J. Apaza, F. Valga, Rocío Zamora, A. Marschall, Michael Cieza, J. Deira, and M. Rodeles. “Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?” Biomedicines, 2023.
J. Halimi. “[SGLT2 Inhibitors: A New Era for Our Patients].” Néphrologie & Thérapeutique, 2021.
J. Menne, E. Dumann, H. Haller, and B. Schmidt. “Effect of SGLT-2 Inhibition on Acute Kidney Injury: A Systematic Review and Meta-Analysis.” Social Science Research Network, 2019.
J. Navarro-González, C. Ferri, E. Martín-Núñez, J. Donate-Correa, N. Pérez-Delgado, C. Hernández-Carballo, Fátima Sánchez-Quintana, VICTOR GARCIA TAGUA, Carol Prieto-Morin, and C. Mora-Fernández. “P1008THERAPY WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS INCREASES KLOTHO IN TYPE 2 DIABETIC PATIENTS,” 2020.
J. O’Sullivan. “Prevention of Cardiovascular Disease and Renal Failure in Type 2 Diabetes: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors.” BMJ Evidence-Based Medicine, 2019.
J. Seufert, and K. Laubner. “Outcome-Studien Zu SGLT-2-Inhibitoren.” Der Internist, 2019.
J. Stephens, K. Brown, and T. Min. “Chronic Kidney Disease in Type 2 Diabetes: Implications for Managing Glycaemic Control, Cardiovascular and Renal Risk.” Diabetes, Obesity and Metabolism, 2020.
Jae Hyun Bae. “SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.” Diabetes & Metabolism Journal, 2025.
Jaehyun Bae, Eun-Gee Park, Sunhee Kim, S. Kim, S. Hahn, and Nam Hoon Kim. “Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Scientific Reports, 2019.
Jennifer B. Green, and P. McCullough. “Roles for SGLT2 Inhibitors in Cardiorenal Disease.” CardioRenal Medicine, 2022.
Jingfeng Qian, and Yanqiu Xu. “Impact of Diabetes on the Effects of SGLT2 Inhibitors on Kidney Outcomes: An Updated Drug/Dose-Dependent Meta-Analysis.” Clinical Nephrology, 2025.
Joseph E Cruz, T. Ahuja, and M. Bridgeman. “Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.” The Annals of Pharmacotherapy, 2018.
Josselin Nespoux, and V. Vallon. “SGLT2 Inhibition and Kidney Protection.” Clinical Science, 2018.
Junhua Ma, Jiancan Lu, Peiling Shen, Xuemei Zhao, and Hongling Zhu. “Comparative Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.” Renal Failure, 2023.
K. J. Chun, and H. Jung. “SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-Analysis of Randomized Controlled Trials.” Kidney Medicine, 2021.
K. Lo, F. Gul, Pradhum Ram, Aaron Y. Kluger, K. Tecson, P. McCullough, and J. Rangaswami. “The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.” CardioRenal Medicine, 2019.
K. Rådholm, Jason H. Y. Wu, M. Wong, C. Foote, G. Fulcher, K. Mahaffey, V. Perkovic, and B. Neal. “Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Disease, Death and Safety Outcomes in Type 2 Diabetes - A Systematic Review.” Diabetes Research and Clinical Practice, 2018.
K. Stavropoulos, K. Imprialos, N. Stavropoulos, S. Bouloukou, G. Kerpiniotis, K. Dimitriadis, C. Tsioufis, and M. Doumas. “Sodium-Glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.” Cardiovascular & Haematological Disorders - Drug Targets, 2018.
Kaden K. Fujita, F. Ye, David Collister, S. Klarenbach, D. Campbell, Derek S. Chew, Amity E. Quinn, P. Ronksley, and Darren Lau. “123-OR: SGLT2 Inhibitors Are Associated with Kidney Benefits at All Degrees of Proteinuria—A Cohort Study.” Diabetes, 2023.
Kaori Kitaoka, Yuichiro Yano, H. Nagasu, H. Kanegae, Noriharu Chishima, Hiroki Akiyama, Kouichi Tamura, and Naoki Kashihara. “Kidney Outcomes of SGLT2 Inhibitors Among Older Patients with Diabetic Kidney Disease in Real-World Clinical Practice: The Japan Chronic Kidney Disease Database Ex.” BMJ Open Diabetes Research & Care, 2024.
Kazuo Kobayashi, M. Toyoda, Moritsugu Kimura, N. Hatori, T. Furuki, H. Sakai, M. Takihata, et al. “Retrospective Analysis of Effects of Sodium-Glucose Co-Transporter 2 Inhibitor in Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease.” Diabetes & Vascular Disease Research, 2018.
Kazuo Kobayashi, M. Toyoda, N. Hatori, Nobumichi Saito, T. Kanaoka, H. Sakai, T. Furuki, et al. “Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium–Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.” Diabetes Technology & Therapeutics, 2020.
Keiji Hirai, Junki Morino, Saori Minato, S. Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, et al. “The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.” Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2020.
Kelsey M Leite, Allissa M. Long, M. Ostroff, Leanna Borges, and G. Braden. “A Review of the Renoprotective Effects of Novel Antidiabetic Agents.” Journal of Pharmacy and Practice, 2020.
L. Fang, J. Duan, Jinsong Geng, Zhangsuo Liu, and Jiancheng Dong. “Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for the Prevention and Treatment of Diabetic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.” Diabetic Nephropathy, 2021.
L. Sloan. “SGLT2 Inhibitors Across the Spectrum of Chronic Kidney Disease: A Narrative Review.” Postgraduate Medicine, 2024.
Linda Sukiatno, I. Y. Kusuma, and Galih Samodra. “Cardioprotective and Renoprotective Effects of the Use of SGLT2 Inhibitors in Diabetes Mellitus Patients.” Proceedings of the International Conference on Health and Medical Sciences (AHMS 2020), 2021.
Louise Woodhams, L. Chalmers, T. F. Sim, B. Yeap, M. Schlaich, C. Schultz, and G. Hillis. “Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors Plus Standard Care in Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.” Journal of Diabetes and Its Complications, 2023.
Lubin Xu, Yang Li, Jiaxin Lang, P. Xia, Xinyu Zhao, Li Wang, Yang Yu, and Limeng Chen. “Effects of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition on Renal Function and Albuminuria in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.” PeerJ, 2017.
M. A. Podestà, Gianmarco Sabiu, A. Galassi, P. Ciceri, and M. Cozzolino. “SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease.” Biomedicines, 2023.
M. Baker, and M. Perazella. “SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: Is Acute Kidney Injury a Concern?” JN. Journal of Nephrology (Milano. 1992), 2020.
M. Ibernon, Maru Navarro, Montserrat Gomà, Ariel Tango, O. Rap, Cristina Cabrera, Ana Sánchez, Neus Rodriguez, and Pilar Ruiz. “#1626 The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Nephropathy and Non Diabetic Renal Disease in Diabetes Mellitus Type 2 Patients.” Nephrology, Dialysis and Transplantation, 2024.
M. Kanai, Kazuhiro Kimura, Hirohiko Motoki, Sho Suzuki, Takahiro Okano, M. Minamisawa, K. Yoshie, et al. “Cardio-Renal Protective Effects of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Severely Impaired Renal Function.” European Heart Journal, 2021.
M. Provenzano, M. Pelle, I. Zaffina, B. Tassone, R. Pujia, Marco Ricchio, R. Serra, et al. “Sodium-Glucose Co-Transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.” Frontiers in Medicine, 2021.
M. Wani, and Tariq A Bhat. “News and Views.” JMS SKIMS, 2019.
Mahmoud Barbarawi, Ahmad Al-Abdouh, O. Barbarawi, Harini Lakshman, Mariam Al kasasbeh, and Kai Chen. “SGLT2 Inhibitors and Cardiovascular and Renal Outcomes: A Meta-Analysis and Trial Sequential Analysis.” Heart Failure Reviews, 2021.
Meir Schechter, and Ofri Mosenzon. “[IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].” Harefuah, 2021.
Merlin C. Thomas, B. Neuen, S. Twigg, M. Cooper, and S. Badve. “SGLT2 Inhibitors for Patients with Type 2 Diabetes and CKD: A Narrative Review.” Endocrine Connections, 2023.
“Metaanalyse Bestätigt Renoprotektive Effekte von SGLT2-Inhibitoren.” Diabetologie Und Stoffwechsel, 2020.
Michael S. Kelly, Jelena Lewis, Ashley M. Huntsberry, Lauren Dea, and I. Portillo. “Efficacy and Renal Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease.” Postgraduate Medicine, 2018.
Mohammed D. Algethami, Sami A. Alzahrani, Bander H. Alessa, A. N. B. Madhi, H. M. Alzahrani, and Rami S. Altwairqi. “Sodium‐glucose Co‐transporter Protein 2 Inhibitors for Long-Term Kidney Function Preservation in Type 2 Diabetes with Chronic Kidney Disease: A Meta-Analysis of Rates of Progression to End-Stage Renal Disease.” International Journal of Community Medicine and Public Health, 2024.
Mohanad Almaimani, V. Sridhar, and D. Cherney. “Sodium-Glucose Cotransporter 2 Inhibition in Non-Diabetic Kidney Disease.” Current Opinion in Nephrology and Hypertension, 2021.
N. Kashihara, Kengo Kidokoro, and E. Kanda. “Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Underlying Mechanisms.” Current Opinion in Nephrology and Hypertension, 2019.
N. Mikhail. “SGLT2 Inhibitors for Treatment of Diabetic Nephropathy.” Current Research in Diabetes & Obesity Journal, 2019.
N. Mittal, Vikas Sehray, Rakesh Mittal, and Surjit Singh. “Reno-Protective Potential of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors: Summary Evidence from Clinical and Real-World Data.” European Journal of Pharmacology, 2021.
N. Saldanha, M. Shah, Monika Dalal, Z. Virani, I. Parekh, H. Vora, P. Rajput, S. Tapiawala, and B. Shah. “A Prospective Study to Evaluate the Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients with Chronic Kidney Disease.” Journal of Diabetology, 2022.
Nahla Hussein, F. Abdelrahman, Abdelrahman Khedr, H. Aref, M. Halawa, and Magdy Elsharkawy. “EFFECT OF SODIUM GLUCOSE CO TRANSPORTER 2 INHIBITOR ON PROTEINURIA IN DIABETIC PATIENTS.” The Quarterly Journal of Medicine, 2021.
Nam Hoon Kim, and N. Kim. “Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.” Diabetes & Metabolism Journal, 2022.
Nicole Felix, M. Gauza, L. Teixeira, M. E. S. Guisso, Alleh Nogueira, C. Dagostin, A. Godoi, et al. “Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis.” Korean Circulation Journal, 2024.
Ning Li, Dan Lv, Xiangjun Zhu, P. Wei, Y. Gui, Shijia Liu, Enchao Zhou, Min Zheng, Dong Zhou, and Lu Zhang. “Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis.” Frontiers in Medicine, 2021.
O. González-Albarrán, Cristóbal Morales, M. Pérez-Maraver, J. J. Aparicio-Sánchez, and R. Simó. “Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.” Diabetes Therapy, 2022.
Ofri Mosenzon, S. Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, S. Murphy, et al. “Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients with Type 2 Diabetes: An Analysis from the DECLARE-TIMI 58 Randomised Trial.” The Lancet Diabetes and Endocrinology, 2019.
P. Au, K. Tan, B. Cheung, I. Wong, H. Li, and C. Cheung. “Association Between SGLT2 Inhibitors Vs DPP4 Inhibitors and Renal Outcomes Among Patients with Type 2 Diabetes.” Journal of Clinical Endocrinology and Metabolism, 2022.
P. Delanaye, and A. Scheen. “[EMPA-KIDNEY: Empagliflozin in Chronic Kidney Disease].” Revue Medicale de Liege, 2023.
P. Georgianos, M. Divani, T. Eleftheriadis, P. Mertens, and V. Liakopoulos. “SGLT-2 Inhibitors in Diabetic Kidney Disease: What Lies Behind Their Renoprotective Properties?” Current Medicinal Chemistry, 1969.
P. Georgianos, T. Eleftheriadis, and V. Liakopoulos. “Combination Therapy with an SGLT‐2 Inhibitor and Finerenone in DKD: Are We There yet?” European Journal of Clinical Investigation, 2022.
P. Georgianos, V. Vaios, E. Dounousi, M. Salmas, T. Eleftheriadis, and V. Liakopoulos. “Mechanisms of Cardiorenal Protection with SGLT-2 Inhibitors.” Current Pharmaceutical Design, 2021.
P. Georgianos, V. Vaios, S. Roumeliotis, K. Leivaditis, T. Eleftheriadis, and V. Liakopoulos. “Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.” Journal of Personalized Medicine, 2022.
P. Mark, P. Sarafidis, R. Ekart, C. Ferro, Olga Balafa, B. Fernandez-Fernandez, W. Herrington, et al. “SGLT2i for Evidence-Based Cardiorenal Protection in Diabetic and Non-Diabetic Chronic Kidney Disease: A Comprehensive Review by EURECA-m and ERBP Working Groups of ERA.” Nephrology, Dialysis and Transplantation, 2023.
P. Natale, David J. Tunnicliffe, Tadashi Toyama, S. Palmer, V. Saglimbene, M. Ruospo, L. Gargano, G. Stallone, Loreto Gesualdo, and G. Strippoli. “Sodium-Glucose Co-Transporter Protein 2 (SGLT2) Inhibitors for People with Chronic Kidney Disease and Diabetes.” Cochrane Database of Systematic Reviews, 2024.
P. Sarafidis, A. Ortiz, C. Ferro, J. Halimi, R. Kreutz, F. Mallamaci, G. Mancia, and C. Wanner. “Sodium--Glucose Co-Transporter-2 Inhibitors for Patients with Diabetic and Nondiabetic Chronic Kidney Disease: A New Era Has Already Begun.” Journal of Hypertension, 2021.
P. Sarafidis, C. Ferro, E. Morales, A. Ortiz, J. Małyszko, R. Hojs, K. Khazim, et al. “SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Nephroprotection and Cardioprotection in Patients with Diabetes Mellitus and Chronic Kidney Disease. A Consensus Statement by the EURECA-m and the DIABESITY Working Groups of the ERA-EDTA.” Nephrology, Dialysis and Transplantation, 2019.
Prabhat Singh, Lokesh Goyal, D. Mallick, Salim R Surani, and K. Yashi. “Role of Sodium-Glucose Co-Transporter 2 Inhibitors in Chronic Kidney Disease, Congestive Heart Failure and Stroke—A Review and Clinical Guide for Healthcare Professionals.” Journal of Clinical Medicine, 2023.
R. DeFronzo, and M. Abdul-Ghani. “Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney.” Diabetes Spectrum, 2021.
R. Fontes‐Carvalho, D. Santos-Ferreira, I. Raz, N. Marx, F. Ruschitzka, and F. Cosentino. “Protective Effects of SGLT-2 Inhibitors Across the Cardiorenal Continuum: Two Faces of the Same Coin.” European Journal of Preventive Cardiology, 2021.
R. Gilbert, and K. Thorpe. “Acute Kidney Injury with Sodium‐glucose Co‐transporter‐2 Inhibitors: A Meta‐analysis of Cardiovascular Outcome Trials.” Diabetes, Obesity and Metabolism, 2019.
R. Guthrie. “Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.” Postgraduate Medicine, 2018.
R. Nevola, Maria Alfano, P. Pafundi, Chiara Brin, F. Gragnano, P. Calabrò, L. Adinolfi, L. Rinaldi, F. C. Sasso, and A. Caturano. “Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.” Reviews in Cardiovascular Medicine, 2022.
Rasha O. Abdelmoniem, M. S. Shaalan, M. Shawky, Walla M. lbrahim, and Ayman M. Elbadawy. “Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients.” The Egyptian Journal of Hospital Medicine, 2022.
Renata Carvalho, Bárbara Ribeiro, J. Medeiros, J. M. Bastos, R. Vaz, Sofia Marques, and António Rmalheiro. “MO654REAL LIFE EXPERIENCE AFTER 20 MONTHS USING SGLT2 INHIBITORS,” 2021.
S. A. Alharbi, A. AlQahtani, Shahad Alnasser, Ghadeer L. Alfuhaydi, Raghad Adel Alrowithi, Fawzia Ayedh Asiri, and Ahmed Ammar Almutairi. “Evaluating the Efficacy of SGLT2 Inhibitors in Preventing Diabetic Kidney Disease.” Journal of Healthcare Sciences, 2025.
S. Cabrera, R. Torres, L. Elgueta, E. Segovia, M. Sanhueza, A. Boltansky, and M. Alvo. “P1011ATHE SGTL-2 INHIBITORS DECREASE THE MORTALITY AND PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD) IN TYPE 2 DIABETES PATIENTES. SYSTEMATIC REVIEW AND META-ANALYSIS OF THE LITERATURE,” 2020.
S. De Cosmo, F. Viazzi, P. Piscitelli, G. Leoncini, A. Mirijello, B. Bonino, and R. Pontremoli. “Impact of CVOTs in Primary and Secondary Prevention of Kidney Disease.” Diabetes Research and Clinical Practice, 2019.
S. Luciano, W. Li, and J. O'Rourke. “PUK2 Assessing Mortality Risk and Renal Outcomes in Chronic Kidney Disease Patients Treated with Sglt-2 Inhibitors or DPP-4 Inhibitors: A Real-World Study,” 2020.
S. Rabizadeh, M. Nakhjavani, and A. Esteghamati. “Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.” International Journal of Endocrinology and Metabolism, 2019.
S. Rehman, and Faiqa Rahman. “Sodium-Glucose Cotransporter 2 Inhibitors and Their Renal Benefits in Type 2 Diabetes : A Systematic Review,” 2020.
S. Seidu, S. Kunutsor, X. Cos, S. Gillani, and K. Khunti. “SGLT2 Inhibitors and Renal Outcomes in Type 2 Diabetes with or Without Renal Impairment: A Systematic Review and Meta-Analysis.” Primary Care Diabetes, 2018.
S. Sugiyama, H. Jinnouchi, Akira Yoshida, K. Hieshima, Noboru Kurinami, K. Jinnouchi, Motoko Tanaka, et al. “Renoprotective Effects of Additional SGLT2 Inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.” Journal of Clinical Medicine Research, 2019.
Saeko Sato, K. Takayanagi, Taisuke Shimizu, K. Kanozawa, Takatsugu Iwashita, and Hajime Hasegawa. “Correlation Between Albuminuria and Interstitial Injury Marker Reductions Associated with SGLT2 Inhibitor Treatment in Diabetic Patients with Renal Dysfunction.” European Journal of Medical Research, 2022.
Sahithi Reddy Kalluri, T. Bhutta, Hanan Hannoodee, Mahmoud Al Khalili, Nyein Wint Yee Theik, Oluwatimilehin E Raji, Priya Shenwai, Rutul Shah, and Safeera Khan. “Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review.” Cureus, 2021.
Sarah Yoon Ai Ng, D. Zhu, and W. Herrington. “In Type 2 Diabetes, SGLT-2 Inhibitors Reduce Risk for Major Kidney Outcomes.” Annals of Internal Medicine, 2020.
Shafaat Raza, S. Osasan, Sudiksha Sethia, Tayyaba Batool, Zarna Bambhroliya, Joel Sandrugu, Michael Lowe, Oluwasemilore Okunlola, and Pousette Hamid. “A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection.” Cureus, 2022.
Shaowei Pang, and Xiaoli Li. “Early Use of SGLT2 Inhibitors Reduces the Progression of Diabetic Kidney Disease: A Retrospective Cohort Study.” American Journal of Translational Research, 2024.
Shuo Yang, W. He, Lu Zhao, and Yaochuan Mi. “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with Kidney Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.” PLoS ONE, 2022.
Sidra Jamil, Arfa Zainab, Avneet Arora, T. Shaik, Vimal Khemani, Favour C Mekowulu, Yared N Aschalew, and Saima Khan. “Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-Analysis of Randomized Control Trials.” Cureus, 2022.
Susovan Halder, Arnab Bhattacharyya, Shatavisa Mukherjee, Bhaswar Konar, and Antareep Halder. “Assessment of Effects of Combination of SGLT2 Inhibitors and Renin–Angiotensin–Aldosterone System Blockers on the Renal Functions of Patients of Diabetic Kidney Disease (SGRASS-DKD Study).” Journal of Diabetology, 2024.
T. Jansz, K. G. Young, R. Hopkins, A. McGovern, B. Shields, A. Hattersley, A. G. Jones, et al. “Precision Medicine in Type 2 Diabetes: Targeting SGLT2-Inhibitor Treatment For Kidney Protection.” medRxiv, 2024.
T. Milder, S. Stocker, D. Samocha-Bonet, R. Day, and J. Greenfield. “Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes—Cardiovascular and Renal Benefits in Patients with Chronic Kidney Disease.” European Journal of Clinical Pharmacology, 2019.
T. Oh, J. Moon, K. Hur, Seung-Hyun Ko, Hyun Jung Kim, Taehee Kim, D. Lee, and M. Moon. “Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement.” Kidney Research and Clinical Practice, 2020.
———. “Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement.” Diabetes & Metabolism Journal, 2020.
T. Siddiqi, David Z. I. Cherney, H. Siddiqui, T. Jafar, J. Januzzi, Muhammad Shahzeb Khan, Adeera Levin, et al. “Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes Across Baseline Cardiovascular-Kidney-Metabolic Conditions.” Journal of the American Society of Nephrology, 2024.
T. Siddiqi, Muhammad Shariq S Usman, H. Siddiqui, and J. Butler. “Abstract 14614: Effect of SGLT2 Inhibitors on Renal Outcomes Across Various Patient Populations.” Circulation, 2023.
T. Toyama, B. Neuen, M. Jun, T. Ohkuma, B. Neal, M. Jardine, H. Heerspink, et al. “Effect of SGLT2 Inhibitors on Cardiovascular, Renal and Safety Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta‐analysis.” Diabetes, Obesity and Metabolism, 2019.
Taichi Nagahisa, and Y. Saisho. “Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.” Diabetes Therapy, 2019.
Takayuki Yamada, M. Wakabayashi, Abhinav Bhalla, N. Chopra, H. Miyashita, Takahisa Mikami, H. Ueyama, et al. “Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.” Cardiovascular Diabetology, 2020.
Taro Hirai, Munehiro Kitada, I. Monno, E. Oda, Yoshihiro Hayashi, Keiji Shimada, Y. Takagaki, et al. “SGLT2 Inhibitors in Type 2 Diabetic Patients with Renal Function Impairment Slows the Annual Renal Function Decline, in a Real Clinical Practice.” Journal of Diabetes Investigation, 2021.
Tatsuya Ishibashi, Shuhei Morita, H. Furuta, Masahiro Nishi, and Taka-aki Matsuoka. “Renoprotective Potential of Concomittant Medications with SGLT2 Inhibitors and Renin-Angiotensin System Inhibitors in Diabetic Nephropathy Without Albuminuria: A Retrospective Cohort Study.” Scientific Reports, 2023.
Thomas A. Mavrakanas, Michael A. Tsoukas, James M. Brophy, Abhinav Sharma, and Karim Gariani. “SGLT-2 Inhibitors Improve Cardiovascular and Renal Outcomes in Patients with CKD: A Systematic Review and Meta-Analysis.” Scientific Reports, 2023.
Thomas A. Zelniker, S. Wiviott, I. Raz, K. Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, et al. “SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials.” The Lancet, 2019.
Tianbiao Zhou, Kaijin Yao, Yina Xie, Yongda Lin, Jiali Wang, and Xiutian Chen. “Renal Protection and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.” Current Pharmaceutical Design, 2023.
Tien-Jyun Chang, Yen-Chieh Lee, Li-Chiu Wu, and Chia-Hsuin Chang. “Albuminuria‐based Stratification of End‐stage Kidney Disease Progression and Mortality with Sodium‐glucose Cotransporter 2 Inhibitors (SGLT2i): A Retrospective Cohort Study in Type 2 Diabetes and Chronic Kidney Disease.” Pharmacotherapy, 2024.
Ting Liu, Rui Li, Xiaoxia Wang, Xingxing Gao, and Xiaodong Zhang. “Benefits of SGLT2 Inhibitors Combining with Renin-Angiotensin-System Blockers on Cardiovascular Outcomes in Chronic Kidney Disease Patients: A Systemic Review and Meta-Analysis.” Medicina Clínica (Ed. Impresa), 2021.
V. Salukhov, Y. Khalimov, S. Shustov, and S. Popov. “SGLT2 Inhibitors and Kidneys: Mechanisms and Main Effects in Diabetes Mellitus Patients.” Diabetes Mellitus, 2021.
V. Sridhar, B. Neuen, Robert A. Fletcher, A. Slee, F. Ang, W. Rapattoni, Clare Arnott, et al. “Kidney Protection with Canagliflozin: A Combined Analysis of the Randomized CANVAS Program and CREDENCE Trials.” Diabetes, Obesity and Metabolism, 2023.
V. Sridhar, H. Rahman, and D. Cherney. “What Have We Learned about Renal Protection from the Cardiovascular Outcome Trials and Observational Analyses with SGLT2 Inhibitors?” Diabetes, Obesity and Metabolism, 2020.
V. Sridhar, K. Tuttle, and D. Cherney. “We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.” American Journal of Kidney Diseases, 2020.
V. Tesar. “SGLT2 Inhibitors in Non-Diabetic Kidney Disease.” Advances in Clinical and Experimental Medicine, 2022.
V. Tsimihodimos, T. Filippatos, and Moses Elisaf. “SGLT2 Inhibitors and the Kidney: Effects and Mechanisms.” Diabetes & Metabolic Syndrome, 2018.
Vjollca Godanci-Kelmendi, Mimoza Ramadani Piraj, Fatime Imeri, and Shega Konjufca. “#3286 Safety and Efficacy of SGLT2 Inhibitors in the Elderly with CKD.” Nephrology, Dialysis and Transplantation, 2025.
Vjollca Godanci-Kelmendi, Mimoza Ramadani Piraj, Fatime Ymeri, and Shega Konjufca. “#3008 SERENDIPITY OF SGLT2 INHIBITION – DIABETIC AND NON DIABETIC CKD.” Nephrology, Dialysis and Transplantation, 2023.
Wajd Alkabbani, Arsène Zongo, J. Minhas-Sandhu, D. Eurich, B. Shah, M. Alsabbagh, and J. Gamble. “Renal Effectiveness and Safety of the Sodium-Glucose Cotransporter-2 Inhibitors: A Population-Based Cohort Study.” BMJ Open Diabetes Research & Care, 2021.
Wendy Wang, Paul Drawz, Lisa S. Chow, Lin Y Chen, Rob F. Walker, F. Norby, and P. Lutsey. “Abstract 35: Association of SGLT2 Inhibitors and Other Second Line Therapies With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes.” Circulation, 2024.
X. Jian, Q-L Yang, S. Xiao, Z. Jing, and S-D Hu. “The Effects of a Sodium-Glucose Cotransporter 2 Inhibitor on Diabetic Nephropathy and Serum Oxidized Low-Density Lipoprotein Levels.” European Review for Medical and Pharmacological Sciences, 2018.
Xiaoya Sun, and Guohong Wang. “Renal Outcomes with Sodium-Glucose Cotransporters 2 Inhibitors.” Frontiers in Endocrinology, 2022.
Y. Saisho. “SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?” Diseases, 2020.
Yan Xie, Benjamin Bowe, Andrew K. Gibson, J. McGill, G. Maddukuri, Yan Yan, and Z. Al-Aly. “Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.” Diabetes Care, 2020.
Yanqun Zheng, and Jia Sun. “Long-Term Effect of Sodium–Glucose Cotransporter 2 Inhibitors in Kidney Functions: A Systematic Review and Meta-Analysis.” Medicine, 2025.
Yaoming Xue, Li-xin Shi, Xu Yu, Yangang Wang, Tianpei Hong, Xiaoying Li, Jia-yun Ma, Dalong Zhu, and Yiming Mu. “931-P: Real-World Study on the Effect of SGLT2 Inhibitors in Patients with Type 2 Diabetes in China.” Diabetes, 2024.
Yuki Kawai, Kazushi Uneda, Takayuki Yamada, S. Kinguchi, Kazuo Kobayashi, K. Azushima, T. Kanaoka, Y. Toya, H. Wakui, and K. Tamura. “Comparison of Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients with/Without Albuminuria: A Systematic Review and Network Meta-Analysis.” Diabetes Research and Clinical Practice, 2021.
Zhi-Cheng Dai, Jin-Xia Chen, Rong Zou, Xuan-Bing Liang, Ji-Xin Tang, and Cui-Wei Yao. “Role and Mechanisms of SGLT-2 Inhibitors in the Treatment of Diabetic Kidney Disease.” Frontiers in Immunology, 2023.
Владимир Владимирович Салухов, Юрий Шавкатович Халимов, С. Б. Шустов, and Сергей Игоревич Попов. “Ингибиторы SGLT2 и Почки: Механизмы и Основные Эффекты у Больных Сахарным Диабетом 2 Типа,” 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Afrizal Adi Nugroho, Fatimah Yasin (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
